Group 1 - The core point of the article is that Jincheng Pharmaceutical (300233) announced that its subsidiary, Jincheng Jinsu, received approval from the National Medical Products Administration for the supplementary application of injectable Cefodizime Sodium (0.5g, 1.0g), which has passed the consistency evaluation of quality and efficacy for generic drugs [1] - Injectable Cefodizime Sodium is a third-generation cephalosporin primarily used for infections caused by sensitive bacteria such as Streptococcus and Pneumococcus [1] - According to the data from the China Pharmaceutical Market, the sales revenue of injectable Cefodizime Sodium in public medical institutions in China is projected to be 1.074 billion RMB in 2022, 675 million RMB in 2023, and 394 million RMB in 2024 [1]

证券代码：300233 证券简称：金城医药 公告编号：2025-048 二、药品相关信息 头孢地嗪钠是第三代头孢菌素，临床上主要用于链球菌属、肺炎球菌等敏感 菌所致的肺炎、支气管炎、咽喉炎、扁桃体炎、肾盂肾炎、尿路感染、淋菌性尿 道炎、胆囊炎、胆管炎、妇科感染、败血症及中耳炎等。 中国为头孢地嗪钠主流销售国家。米内网显示 2022 年至 2024 年国内公立医 疗全规格注射用头孢地嗪钠销售额分别为：10.74 亿元人民币、6.75 亿元人民币、 3.94 亿元人民币。截至本公告披露日，国内注射用头孢地嗪钠已批准上市的厂家 包括山东罗欣药业集团股份有限公司、丽珠集团丽珠制药厂、华北制药河北华民 药业有限责任公司、苏州东瑞制药有限公司等企业。 三、对公司的影响及风险提示 本次金城金素获得注射用头孢地嗪钠药品补充申请批准通知书，能够丰富公 司产品线，有利于提升产品的市场竞争力。由于药品销售受国家政策、市场环境 等不确定因素的影响，敬请广大投资者注意风险，理性投资。 山东金城医药集团股份有限公司 关于子公司收到药品补充申请批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导 ...

Group 1 - The core point of the article is that Jincheng Pharmaceutical (300233) announced that its subsidiary, Jincheng Jinsu, received approval from the National Medical Products Administration for a supplemental application for injectable Cefmetazole Sodium in various specifications [1] - The approved specifications include 0.25g, 1.0g, and 2.0g, and the drug approval number has been issued with a validity period of 18 months [1] - According to the data from Minet, the sales revenue of injectable Cefmetazole Sodium in domestic public medical institutions is projected to be 1.337 billion RMB, 1.277 billion RMB, and 1.334 billion RMB for the years 2022, 2023, and 2024 respectively [1]

证券代码：300233 证券简称：金城医药 公告编号：2025-047 山东金城医药集团股份有限公司 关于子公司收到药品补充申请批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 山东金城医药集团股份有限公司控股子公司广东金城金素制药有限公司（以 下简称"金城金素"）于近日收到国家药品监督管理局下发的注射用头孢美唑钠 （0.25g、0.5g、1.0g、2.0g）药品补充申请批准通知书（通知书编号：2025B02726、 2025B02725、2025B02727、2025B02723），该药品通过仿制药质量和疗效一致性 评价。现将相关情况公告如下： 山东金城医药集团股份有限公司董事会 2025 年 6 月 27 日 | | | | 44 号）、《关于仿制药质量和疗效一 | | --- | --- | --- | --- | | | 1 瓶/ | 国药准字 | 致性评价工作有关事项的公告》 | | 1.0g | 盒；10 | | （2017 年第 100 号）和《国家药监局 | | | 瓶/盒 | H20258106 | 关于开展化学药品注射剂仿制 ...

Group 1 - The smart medical sector is experiencing a significant upward trend, with notable stock price increases for several companies [1] - Jincheng Pharmaceutical (300233) has seen its stock rise by over 10% [1] - Heertai (002402) and Weining Health (300253) have both increased by over 9% [1] - Yaoshi Technology (300725) has experienced a stock price increase of over 5% [1] - Other companies such as Yuandong Biology and Chengdu Xian Dao are also showing upward movement [1]

证券代码：300233 证券简称：金城医药 公告编号：2025-046 关于泊沙康唑原料药取得 FDA 注册批准函的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 山东金城医药集团股份有限公司（以下简称"金城医药"或"公司"）全资 子公司山东金城昆仑药业有限公司收到美国食品药品监督管理局（以下简称 "FDA"）签发的泊沙康唑原料药（以下简称"本品"）注册批准函 DMF First Adequate Letter（以下简称"FA Letter"）。现将相关情况公告如下： 一、基本情况 药品名称：泊沙康唑/Posaconazole 药品分类：原料药 持有人：山东金城昆仑药业有限公司 药品主文件(DMF)：037734 山东金城医药集团股份有限公司 二、其他相关信息 公司于 2022 年 11 月向 FDA 首次递交本品 DMF 并获登记号，于 2025 年 6 月 24 日获得药品注册批准函 FA Letter。泊沙康唑是由伊曲康唑衍生出的第二代三 唑类抗真菌药，用于成人患者的侵袭性曲霉病的治疗和预防 13 岁和 13 岁以上因 重度免疫缺陷而导致侵袭性曲霉 ...

Core Insights - Jincheng Pharmaceutical has experienced significant growth since its listing in June 2011, with its market capitalization increasing from 2.465 billion yuan to 5.862 billion yuan, reflecting a deep focus on the pharmaceutical intermediate sector [1][6] - The company's main business includes the research, production, and sales of cephalosporin antibiotic intermediates, with the highest revenue contribution coming from formulation products at 35.30% [3] - Over the 14 years since its IPO, Jincheng Pharmaceutical has achieved a cumulative profit growth of 251.45%, with net profit reaching 197 million yuan in the latest fiscal year [3][4] Financial Performance - Revenue has shown stable growth, increasing from 2.962 billion yuan in 2020 to 3.373 billion yuan in 2024 [4] - The company has recovered from a loss of 489 million yuan in 2020 to a net profit of 197 million yuan in 2024, indicating a significant turnaround in profitability [4] - The company's net profit has fluctuated, with 7 out of 14 years showing profit growth, highlighting a volatile earnings trend [3] Market Capitalization - Since its IPO, Jincheng Pharmaceutical's market value has increased by 138%, peaking at 17.555 billion yuan in July 2021 [6] - As of June 20, the company's market capitalization was 5.862 billion yuan, down 11.693 billion yuan from its peak, representing a 66.61% decrease [6]

Macro Dynamics - China will implement zero tariffs on 100% of products for 53 African countries that have established diplomatic relations, enhancing export convenience for the least developed countries in Africa [1] - The China-Africa Cooperation Forum has led to significant development in China-Africa relations, with China being Africa's largest trading partner for 16 consecutive years and new investments exceeding 13.3 billion RMB since the Beijing Summit [2] Automotive Industry - In the first five months of the year, China's automobile sales reached 12.748 million units, with new energy vehicles accounting for 44% of total sales, reflecting a growth of 45.2% in production and 44% in sales for new energy vehicles [3] Financial Institutions - Industrial Securities clarified rumors regarding a potential merger with Huafu Securities, stating that there are no plans for such a merger and that no relevant information has been disclosed [6] - The former deputy governor of China Construction Bank's Anhui branch was expelled from the party due to serious violations of discipline and law, highlighting ongoing regulatory scrutiny in the financial sector [7] Market Data - On June 11, the A-share market saw all three major indices rise, with the Shanghai Composite Index increasing by 0.52% and the Shenzhen Component Index by 0.83%, indicating positive market sentiment [8] - The Hong Kong stock market also experienced gains, with the Hang Seng Index rising by 0.84% and the Hang Seng Tech Index by 1.09%, driven by strong performances from companies like Bilibili and Pop Mart [9] Company Dynamics - Marelli, a global automotive parts giant, filed for Chapter 11 bankruptcy protection to restructure its long-term debt, with 80% of creditors supporting the restructuring plan [11] - Douyin e-commerce announced measures to combat false advertising, targeting merchants and creators engaged in misleading marketing practices [12] - Jin Cheng Pharmaceutical denied rumors of supplying raw materials to international beauty brands, clarifying that the information is not true [13] - Jetstar Asia announced it will cease operations on July 31, reallocating its aircraft to Australian and New Zealand routes, while maintaining other international routes [14]

Core Insights - The company Jin Cheng Pharmaceutical announced the receipt of drug registration certificates for its subsidiary's products, including Posaconazole enteric-coated tablets and injectable Cefoperazone sodium, enhancing its product portfolio in the antifungal and anti-infection sectors [1][2]. Group 1: Product Details - Posaconazole enteric-coated tablets are a second-generation triazole antifungal drug used for treating invasive aspergillosis and preventing infections caused by Aspergillus and Candida species, known for its broad antimicrobial spectrum, high activity, and good safety profile [1]. - Sales of Posaconazole enteric-coated tablets in China's public medical sector were reported as RMB 44.67 million, RMB 76.65 million, and RMB 201.33 million for the years 2021, 2022, and 2023, respectively [1]. - Injectable Cefoperazone sodium is indicated for treating infections caused by sensitive bacteria, including lower respiratory tract infections, urinary tract infections, and sepsis, and is sold in countries such as China, Japan, South Korea, Italy, and India [2]. Group 2: Market Position and Competitors - The main sales market for injectable Cefoperazone sodium is China, with reported sales of RMB 3.442 billion, RMB 4.257 billion, and RMB 4.494 billion for the years 2021, 2022, and 2023, respectively [2]. - Approved manufacturers for Posaconazole enteric-coated tablets in China include Qilu Pharmaceutical (Hainan) Co., Ltd. and Sichuan Kelun Pharmaceutical Co., Ltd. [1]. - Approved manufacturers for injectable Cefoperazone sodium include Chengdu Better Pharmaceutical Co., Ltd., Qilu Anti-Pharmaceutical Co., Ltd., and Harbin Pharmaceutical Group [2]. Group 3: Strategic Implications - The approval of Posaconazole enteric-coated tablets and injectable Cefoperazone sodium enriches the company's product line, which is expected to enhance its market competitiveness in the antifungal and anti-infection fields [2].

Group 1 - Company Jin Cheng Pharmaceutical (300233) announced that its subsidiary Beijing Jin Cheng Tai Er Pharmaceutical Co., Ltd. and its holding subsidiary Guangdong Jin Cheng Jin Su Pharmaceutical Co., Ltd. have received drug registration certificates from the National Medical Products Administration [1] - The drug Posaconazole enteric-coated tablets is a second-generation triazole antifungal medication used for the treatment of invasive aspergillosis and the prevention of invasive aspergillosis and candidiasis infections [1]